CALIBRATION PLASMA

SECTION 2: Hazards identification

According to Regulation (EC) No. 1272/2008 (CLP) Classification of the substance or mixture

Adverse physicochemical, human health and environmental effects

Under normal conditions of use, the mixture does not cause adverse effects to humans and to the environment. Any additional information concerning the risks for health and/or the environment are given in sections 11 and 12 of this sheet

Other hazards which do not result in classification

Warning: This product contains human source material that tested non-reactive for HIV antibody, Hepatitis B Surface Antigen and Anti-HCV at the donor stage. This product, as with all human based specimens, should be handled with proper laboratory safety procedures to minimize the risk of transmission of infectious disease. This substance/mixture does not meet the PBT criteria of REACH regulation, annex XIII This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 %

2.1 Classification of the substance or mixture

Not classified Adverse physicochemical, human health and environmental effects Under normal conditions of use, the mixture does not cause adverse effects to humans and to the environment. Any additional information concerning the risks for health and/or the environment are given in sections 11 and 12 of this sheet. 2.2. Label elements Labelling according to Regulation (EC) No. 1272/2008 [CLP] No labelling applicable 2.3. Other hazards Other hazards which do not result in classification : Warning: This product contains human source material that tested non-reactive for HIV antibody, Hepatitis B Surface Antigen and Anti-HCV at the donor stage. This product, as with all human based specimens, should be handled with proper laboratory safety procedures to minimize the risk of transmission of infectious disease. This substance/mixture does not meet the PBT criteria of REACH regulation, annex XIII This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 % SECTION 3: Composition/information on ingredients 3.1. Substances Not applicable 3.2. Mixtures Comments : Composition: powder containing organic components, human plasma. This mixture does not contain any substances to be mentioned according to the criteria of section 3.2 of REACH Annex II SECTION 4: First aid measures 4.1. Description of first aid measures First-aid measures after inhalation : If inhaled, move person to fresh air. If breathing is difficult, oxygen should be administered. Get medical advice if adverse symptoms appear. First-aid measures after skin contact : Remove contaminated clothes and shoes. Wash immediately affected area with soap or mild detergent and plenty of water until the removal of the mixture (15-20 minutes). Get medical advice if adverse symptoms appear. First-aid measures after eye contact : Wash immediately with plenty of water or normal saline for at least 15 minutes. Keep eyelid open with the finger. Get medical advice if adverse symptoms appear. First-aid measures after ingestion : If swallowed rinse mouth with plenty of water provided person is conscious. Do not induce vomiting. Get medical advice if adverse symptoms appear. 4.2. Most important symptoms and effects, both acute and delayed Symptoms/effects : Acute symptoms and effects are not known. Chronic symptoms : Delayed symptoms and effects are not known. 4.3. Indication of any immediate medical attention and special treatment needed Treat symptomatically. SECTION 5: Firefighting measures 5.1. Extinguishing media Suitable extinguishing media : CO2. Dry powder. Foam. Water spray. 5.2. Special hazards arising from the substance or mixture